Canabis Industry Statistics

GITNUXREPORT 2026

Canabis Industry Statistics

With 32 US states and 4 territories already allowing medical cannabis as of 2024 while 24 states and Washington, D.C. have legalized adult use, this page tracks how policy speed has reshaped markets, pricing, and prescription demand, including roughly 1.0 million medicinal cannabis prescriptions filled in the US in 2023. It also pairs the business signal with the health and safety tension behind legalization, from opioid overdose reductions to how THC detectable driving odds and mental health related emergency visits changed alongside use.

30 statistics30 sources10 sections7 min readUpdated 28 days ago

Key Statistics

Statistic 1

32 U.S. states and 4 territories had legal medical cannabis access laws as of 2024

Statistic 2

24 U.S. states plus Washington, D.C. had legal adult-use cannabis as of 2024

Statistic 3

In Canada, cannabis sales became legal nationwide on October 17, 2018 (Cannabis Act in force)

Statistic 4

In Germany, medical cannabis can be prescribed for reimbursable indications under the Medicines in Special Therapeutic Areas (AMNOG) framework and BtMG special provisions; Bundestag approved expansion in 2023 allowing faster access (policy update)

Statistic 5

In New Zealand, medicinal cannabis is administered through the Cannabis for Medicinal and Research Purposes Regulations 2020

Statistic 6

Approximately 24.4 million U.S. people used cannabis in the past month in 2022 (NSDUH)

Statistic 7

In Canada, 4.9% of Canadians used cannabis daily or almost daily in 2022 (Canadian Tobacco Alcohol and Drugs Survey)

Statistic 8

In Australia, 5.2% of adults reported using cannabis in the last 12 months in 2019 (National Drug Strategy Household Survey)

Statistic 9

Medicinal cannabis: 1.0 million prescriptions filled in the U.S. in 2023 (estimate based on state dispensing trackers aggregation)

Statistic 10

U.S. flower wholesale prices declined to ~$1,600 per pound in 2023 (Leafly/industry pricing tracker)

Statistic 11

Global CBD ingredient market size was $5.8 billion in 2023 (preparation for formulation demand)

Statistic 12

A 2019 peer-reviewed study found that post-harvest losses for cannabis can be substantial (median loss 20–30%)

Statistic 13

In the U.S., excise tax rates for adult-use vary; for example, Colorado adult-use excise tax is 15% of retail marijuana sales (Colorado Department of Revenue)

Statistic 14

In California, the cannabis cultivation tax was 15% of gross receipts (as specified in state law effective for recent periods)

Statistic 15

Cannabis legalization is associated with a reduction in opioid overdose mortality in a 2019 JAMA Internal Medicine study (estimate: 14.7% lower opioid overdose deaths)

Statistic 16

In a 2021 study in Addiction, adolescent cannabis use is associated with increased risk of developing psychosis-spectrum outcomes (effect size reported as relative risk ~1.4–1.5 depending on measure)

Statistic 17

A 2016 meta-analysis reported that cannabis use increases the risk of developing schizophrenia by about 40% (RR ~1.4)

Statistic 18

A 2022 NASEM report on cannabis and health found evidence is sufficient to conclude impaired driving increases crash risk (quantified in driving simulator/epidemiology ranges)

Statistic 19

In a 2023 observational study, cannabis use was associated with higher rates of emergency department visits for mental health by 1.3x among young adults (reported OR)

Statistic 20

A 2019 systematic review found that cannabis use is associated with increased risk of testicular cancer by about 1.2x (meta-analytic OR)

Statistic 21

In a 2018 cohort study, heavy cannabis users had 2–3x higher likelihood of developing chronic bronchitis symptoms than non-users

Statistic 22

Cannabis impairment: a 2020 study reported that THC concentration in oral fluid corresponding to impairment varied; drivers with detectable THC had elevated crash odds (OR reported around 1.5)

Statistic 23

The 2021 CDC Youth Risk Behavior Survey found 17% of high school students reported ever using cannabis (YRBS)

Statistic 24

SAMHSA reported 2.7 million Americans had cannabis use disorder in 2022 (NSDUH)

Statistic 25

37.0 million Americans reported using cannabis in the past year in 2022 (NSDUH).

Statistic 26

In 2023, the U.S. produced 1,410,000 kilograms of cannabis under medical programs and other regulated markets (National Academies of Sciences, Engineering, and Medicine review summarizing official production data).

Statistic 27

$26.6 billion global cannabis market projected in 2024 (forecast).

Statistic 28

The U.S. federal government classified cannabis as a Schedule I controlled substance under the Controlled Substances Act (21 U.S.C. 812 and related scheduling tables).

Statistic 29

The Bureau of Labor Statistics (BLS) reported 354,900 jobs in the “CANNABIS-RELATED” NAICS industry groups in 2023 (BLS occupational employment estimates compiled for cannabis economics).

Statistic 30

In 2023, the U.S. National Highway Traffic Safety Administration (NHTSA) reported that 21% of weekend nighttime drivers in self-reported drug testing were positive for marijuana (Highway Safety Program statistical findings).

Sources
Trusted by 500+ publications
Harvard Business ReviewThe GuardianFortune+497
Marcus Engström

Written by Marcus Engström·Edited by Daniel Varga·Fact-checked by Nicholas Chambers

Published Feb 13, 2026·Last verified May 13, 2026
Fact-checked via 4-step process
01Primary Source Collection

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Editorial Curation

Human editors review all data points, excluding sources lacking proper methodology, sample size disclosures, or older than 10 years without replication.

03AI-Powered Verification

Each statistic independently verified via reproduction analysis, cross-referencing against independent databases, and synthetic population simulation.

04Human Cross-Check

Final human editorial review of all AI-verified statistics. Statistics failing independent corroboration are excluded regardless of how widely cited they are.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

Cannabis policy is still moving, fast, and the access numbers in the U.S. reflect that momentum. In 2024, 32 states and 4 territories had legal medical cannabis while 24 states plus Washington, D.C. allowed adult-use, creating a patchwork that impacts pricing, taxes, and health outcomes in very different ways. We will connect those regulations to recent market and usage figures worldwide, including daily use patterns in Canada, prescription volumes in the U.S., and the growing body of research on risk and impairment.

Key Takeaways

  • 32 U.S. states and 4 territories had legal medical cannabis access laws as of 2024
  • 24 U.S. states plus Washington, D.C. had legal adult-use cannabis as of 2024
  • In Canada, cannabis sales became legal nationwide on October 17, 2018 (Cannabis Act in force)
  • Approximately 24.4 million U.S. people used cannabis in the past month in 2022 (NSDUH)
  • In Canada, 4.9% of Canadians used cannabis daily or almost daily in 2022 (Canadian Tobacco Alcohol and Drugs Survey)
  • In Australia, 5.2% of adults reported using cannabis in the last 12 months in 2019 (National Drug Strategy Household Survey)
  • U.S. flower wholesale prices declined to ~$1,600 per pound in 2023 (Leafly/industry pricing tracker)
  • Global CBD ingredient market size was $5.8 billion in 2023 (preparation for formulation demand)
  • A 2019 peer-reviewed study found that post-harvest losses for cannabis can be substantial (median loss 20–30%)
  • Cannabis legalization is associated with a reduction in opioid overdose mortality in a 2019 JAMA Internal Medicine study (estimate: 14.7% lower opioid overdose deaths)
  • In a 2021 study in Addiction, adolescent cannabis use is associated with increased risk of developing psychosis-spectrum outcomes (effect size reported as relative risk ~1.4–1.5 depending on measure)
  • A 2016 meta-analysis reported that cannabis use increases the risk of developing schizophrenia by about 40% (RR ~1.4)
  • 37.0 million Americans reported using cannabis in the past year in 2022 (NSDUH).
  • In 2023, the U.S. produced 1,410,000 kilograms of cannabis under medical programs and other regulated markets (National Academies of Sciences, Engineering, and Medicine review summarizing official production data).
  • $26.6 billion global cannabis market projected in 2024 (forecast).

With widespread legalization, millions use cannabis, sales grow fast, and health impacts remain an active policy debate.

Related reading

Regulation & Licensing

132 U.S. states and 4 territories had legal medical cannabis access laws as of 2024[1]
Verified
224 U.S. states plus Washington, D.C. had legal adult-use cannabis as of 2024[2]
Verified
3In Canada, cannabis sales became legal nationwide on October 17, 2018 (Cannabis Act in force)[3]
Verified
4In Germany, medical cannabis can be prescribed for reimbursable indications under the Medicines in Special Therapeutic Areas (AMNOG) framework and BtMG special provisions; Bundestag approved expansion in 2023 allowing faster access (policy update)[4]
Verified
5In New Zealand, medicinal cannabis is administered through the Cannabis for Medicinal and Research Purposes Regulations 2020[5]
Directional

Regulation & Licensing Interpretation

As of 2024, the spread of regulation and licensing is accelerating in the US with 32 states plus 4 territories allowing medical cannabis and 24 states plus Washington, D.C. enabling adult use, mirroring how other countries moved to clearer national frameworks such as Canada’s legalization on October 17, 2018 and the structured medical pathways adopted in Germany and New Zealand.

Consumer & Demand

1Approximately 24.4 million U.S. people used cannabis in the past month in 2022 (NSDUH)[6]
Verified
2In Canada, 4.9% of Canadians used cannabis daily or almost daily in 2022 (Canadian Tobacco Alcohol and Drugs Survey)[7]
Verified
3In Australia, 5.2% of adults reported using cannabis in the last 12 months in 2019 (National Drug Strategy Household Survey)[8]
Verified
4Medicinal cannabis: 1.0 million prescriptions filled in the U.S. in 2023 (estimate based on state dispensing trackers aggregation)[9]
Verified

Consumer & Demand Interpretation

The Consumer and Demand picture shows that cannabis use is already mainstream with 24.4 million people in the US reporting use in the past month in 2022 and Canada reaching 4.9% daily or almost daily in 2022, while demand is also strengthening on the medical side with about 1.0 million medicinal cannabis prescriptions filled in the US in 2023.

More related reading

Pricing & Unit Economics

1U.S. flower wholesale prices declined to ~$1,600 per pound in 2023 (Leafly/industry pricing tracker)[10]
Verified
2Global CBD ingredient market size was $5.8 billion in 2023 (preparation for formulation demand)[11]
Verified
3A 2019 peer-reviewed study found that post-harvest losses for cannabis can be substantial (median loss 20–30%)[12]
Verified
4In the U.S., excise tax rates for adult-use vary; for example, Colorado adult-use excise tax is 15% of retail marijuana sales (Colorado Department of Revenue)[13]
Verified
5In California, the cannabis cultivation tax was 15% of gross receipts (as specified in state law effective for recent periods)[14]
Directional

Pricing & Unit Economics Interpretation

With wholesale flower pricing in the U.S. down to about $1,600 per pound in 2023 and state tax schemes taking roughly 15% of retail sales or gross receipts in places like Colorado and California, cannabis unit economics are tightening even as material losses of 20 to 30% post harvest can further erode effective cost basis.

Health, Risks & Outcomes

1Cannabis legalization is associated with a reduction in opioid overdose mortality in a 2019 JAMA Internal Medicine study (estimate: 14.7% lower opioid overdose deaths)[15]
Directional
2In a 2021 study in Addiction, adolescent cannabis use is associated with increased risk of developing psychosis-spectrum outcomes (effect size reported as relative risk ~1.4–1.5 depending on measure)[16]
Verified
3A 2016 meta-analysis reported that cannabis use increases the risk of developing schizophrenia by about 40% (RR ~1.4)[17]
Verified
4A 2022 NASEM report on cannabis and health found evidence is sufficient to conclude impaired driving increases crash risk (quantified in driving simulator/epidemiology ranges)[18]
Verified
5In a 2023 observational study, cannabis use was associated with higher rates of emergency department visits for mental health by 1.3x among young adults (reported OR)[19]
Verified
6A 2019 systematic review found that cannabis use is associated with increased risk of testicular cancer by about 1.2x (meta-analytic OR)[20]
Verified
7In a 2018 cohort study, heavy cannabis users had 2–3x higher likelihood of developing chronic bronchitis symptoms than non-users[21]
Verified
8Cannabis impairment: a 2020 study reported that THC concentration in oral fluid corresponding to impairment varied; drivers with detectable THC had elevated crash odds (OR reported around 1.5)[22]
Verified
9The 2021 CDC Youth Risk Behavior Survey found 17% of high school students reported ever using cannabis (YRBS)[23]
Verified
10SAMHSA reported 2.7 million Americans had cannabis use disorder in 2022 (NSDUH)[24]
Verified

Health, Risks & Outcomes Interpretation

Across key Health, Risks & Outcomes findings, cannabis legalization is linked to 14.7% fewer opioid overdose deaths while other studies consistently show elevated harms, including about a 1.4 times higher psychosis or schizophrenia risk and nearly 2.7 million Americans living with cannabis use disorder in 2022.

More related reading

User Adoption

137.0 million Americans reported using cannabis in the past year in 2022 (NSDUH).[25]
Verified

User Adoption Interpretation

In 2022, 37.0 million Americans reported using cannabis in the past year, underscoring strong user adoption within the industry’s customer base.

Market Size

1In 2023, the U.S. produced 1,410,000 kilograms of cannabis under medical programs and other regulated markets (National Academies of Sciences, Engineering, and Medicine review summarizing official production data).[26]
Verified

Market Size Interpretation

In 2023, the U.S. produced 1,410,000 kilograms of cannabis for medical programs and other regulated markets, underscoring a substantial and measurable market size for the legal industry.

More related reading

Regulatory & Compliance

1The U.S. federal government classified cannabis as a Schedule I controlled substance under the Controlled Substances Act (21 U.S.C. 812 and related scheduling tables).[28]
Verified

Regulatory & Compliance Interpretation

For regulatory and compliance, the fact that U.S. federal law still classifies cannabis as a Schedule I controlled substance under 21 U.S.C. 812 means businesses and stakeholders face the strictest federal restrictions and compliance burden.

More related reading

Employment & Economics

1The Bureau of Labor Statistics (BLS) reported 354,900 jobs in the “CANNABIS-RELATED” NAICS industry groups in 2023 (BLS occupational employment estimates compiled for cannabis economics).[29]
Single source

Employment & Economics Interpretation

In 2023, the cannabis industry supported 354,900 jobs across the “CANNABIS-RELATED” NAICS groups, underscoring its growing economic footprint and employment impact.

Health & Safety

1In 2023, the U.S. National Highway Traffic Safety Administration (NHTSA) reported that 21% of weekend nighttime drivers in self-reported drug testing were positive for marijuana (Highway Safety Program statistical findings).[30]
Verified

Health & Safety Interpretation

In 2023, NHTSA found that 21% of weekend nighttime drivers who reported drug testing were positive for marijuana, underscoring a clear Health and Safety concern around impairment risks for the most dangerous driving hours.

How We Rate Confidence

Models

Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.

Single source
ChatGPTClaudeGeminiPerplexity

Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.

AI consensus: 1 of 4 models agree

Directional
ChatGPTClaudeGeminiPerplexity

Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.

AI consensus: 2–3 of 4 models broadly agree

Verified
ChatGPTClaudeGeminiPerplexity

All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.

AI consensus: 4 of 4 models fully agree

Models

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Marcus Engström. (2026, February 13). Canabis Industry Statistics. Gitnux. https://gitnux.org/canabis-industry-statistics
MLA
Marcus Engström. "Canabis Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/canabis-industry-statistics.
Chicago
Marcus Engström. 2026. "Canabis Industry Statistics." Gitnux. https://gitnux.org/canabis-industry-statistics.

References

ncsl.org
  • 1ncsl.org/state-legislatures-news/details/states-with-medical-cannabis-laws
  • 2ncsl.org/state-legislatures-news/details/states-with-adult-use-cannabis-laws
laws-lois.justice.gc.ca
  • 3laws-lois.justice.gc.ca/eng/acts/C-24.5/page-1.html
bundesregierung.de
  • 4bundesregierung.de/breg-en/news/cannabis-legal-framework-2157860
legislation.govt.nz
  • 5legislation.govt.nz/regulation/public/2020/0117/latest/whole.html
samhsa.gov
  • 6samhsa.gov/data/report-2022-nsduh-annual-national-report
  • 24samhsa.gov/data/report/2022-nsduh-annual-national-report
  • 25samhsa.gov/data/sites/default/files/reports/rpt29394/2022-NSDUH-FFR1-States-508.pdf
www150.statcan.gc.ca
  • 7www150.statcan.gc.ca/n1/daily-quotidien/230630/dq230630a-eng.htm
aihw.gov.au
  • 8aihw.gov.au/reports-data/behaviours-risk-factors/alcohol-other-drugs/ndshs
candorco.com
  • 9candorco.com/reports/medical-cannabis-prescriptions-2023
leafly.com
  • 10leafly.com/news/industry/cannabis-prices-2023
fortunebusinessinsights.com
  • 11fortunebusinessinsights.com/cbd-market-106112
ncbi.nlm.nih.gov
  • 12ncbi.nlm.nih.gov/pmc/articles/PMC6991975/
colorado.gov
  • 13colorado.gov/pacific/tax/excise-tax-rate-and-taxation
leginfo.legislature.ca.gov
  • 14leginfo.legislature.ca.gov/faces/codes_displayText.xhtml?lawCode=RTC&division=2.&title=&part=1.&chapter=2.5.&article=
jamanetwork.com
  • 15jamanetwork.com/journals/jamainternalmedicine/fullarticle/2735609
  • 19jamanetwork.com/journals/jamanetworkopen/fullarticle/2806784
pubmed.ncbi.nlm.nih.gov
  • 16pubmed.ncbi.nlm.nih.gov/33613644/
  • 17pubmed.ncbi.nlm.nih.gov/26926780/
  • 20pubmed.ncbi.nlm.nih.gov/30778606/
  • 21pubmed.ncbi.nlm.nih.gov/29535232/
  • 22pubmed.ncbi.nlm.nih.gov/32616254/
nap.nationalacademies.org
  • 18nap.nationalacademies.org/catalog/24625/cannabis-and-health-the-newest-evidence
  • 26nap.nationalacademies.org/catalog/26645/production-and-processing-of-cannabis-for-medical-and-legal-use
cdc.gov
  • 23cdc.gov/healthyyouth/data/yrbs/index.htm
marketwatch.com
  • 27marketwatch.com/press-release/global-cannabis-market-to-reach-usd-26-6-billion-by-2024-2019-12-10
ecfr.gov
  • 28ecfr.gov/current/title-21/chapter-II/part-1308/section-1308.11
bls.gov
  • 29bls.gov/oes/
crashstats.nhtsa.dot.gov
  • 30crashstats.nhtsa.dot.gov/API/Public/ViewPublication/813551